Conti, Diego M; Vibeke, Backer; Kirsten, Beyer; Leif, Bjermer; Adam, Chaker; Stephanie, Dramburg; Mina, Gaga; Monika, Gappa; Philippe, Gevaert; Eckard, Hamelmann; Hellings, Peter W; Milos, Jesenak; Kopp, Matthias V; Marcus, Maurer; Marcia, Podesta; Dermot, Ryan; Scadding, Glenis K; Eike, Wüstenberg; Ulrich, Wahn and Susanne, Lau (2024). EUFOREUM Berlin 2023: Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus. Pediatric allergy and immunology, 35(7) Wiley-Blackwell 10.1111/pai.14183
|
Text
Pediatric_Allergy_Immunology_-_2024_-_Conti_-_EUFOREUM_Berlin_2023__Optimizing_care_for_type_2_inflammatory_diseases_from.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual forum EUFOREUM in Berlin in November 2023. The aim of EUFOREUM 2023 was to highlight pediatric action plans for prevention and optimizing care for type 2 inflammatory conditions starting in childhood, with a focus on early-stage diagnosis, ensuring neither under- nor overdiagnosis, optimal care, and suggestions for improvement of care. EUFOREA is an international not-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in the keynote lectures and faculty of the virtual EUFOREUM 2023 (www.euforea.eu/euforeum) coming from the pediatric, allergology, pulmonology, ENT, dermatology, primary health care fields and patients around the central theme of type 2 inflammation. As most type 2 inflammatory conditions may start in childhood or adolescence, and most children have type 2 inflammation when suffering from a respiratory or skin disease, the moment has come to raise the bar of ambitions of care, including prevention, remission and disease modification at an early stage. The current report provides a comprehensive overview of key statements by the faculty of the EUFOREUM 2023 and the ambitions of EUFOREA allowing all stakeholders in the respiratory field to be updated and ready to join forces in Europe and beyond.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine 04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Pneumology |
UniBE Contributor: |
Kopp, Matthias Volkmar |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0905-6157 |
Publisher: |
Wiley-Blackwell |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
02 Jul 2024 09:50 |
Last Modified: |
03 Jul 2024 15:21 |
Publisher DOI: |
10.1111/pai.14183 |
PubMed ID: |
38949196 |
Uncontrolled Keywords: |
AD EUFOREA T2‐inflammation allergic rhinitis asthma pediatrics rhinosinusitis |
BORIS DOI: |
10.48350/198350 |
URI: |
https://boris.unibe.ch/id/eprint/198350 |
Actions (login required)
 |
Edit item |